Skip to content
Menu

Ionis Pharmaceuticals, Inc. IONS

Full chart Compare
Set alert

Price alert · IONS

All alert types
27.22 USD -0.17 (-0.62%)

Regular-session close

27.09 -0.13 -0.48%

Pre-market · Nov 20, 4:49 AM ET

26.71 Day range 27.99
26.55 52-week range 86.74
YTD
-65.59%
1 year
-63.22%

5D -0.39 (-1.41%)

272829FriMonTueWedThu27.22
Market cap
4.53B
Revenue (ttm)
960.09M
Profit margin
-56.93%
EPS (ttm)
-3.35
Shares out
166.55M
Forward P/E
-13.43
YTD return
-65.59%
1-year return
-63.22%
50-day average
41.89
200-day average
63.66
Volume
3.06M
Avg volume
3.89M
Open
27.35
Previous close
27.39
Day's range
26.71 – 27.99
52-week range
26.55 – 86.74
Beta
0.40
Analysts
Buy
Price target
67.83 (+149.2%)
Earnings date
Feb 24, 2027

Key statistics

Enterprise value
4.79B
PEG ratio
27.33
Price / sales
4.72
Price / book
11.51
Revenue growth
54.90%
Free cash flow
-371.24M
Total cash
1.94B
Total debt
2.17B
Return on equity
-108.05%
Short % of float
16.84%

Fundamental scorecard

5 of 25 checks passed on IONS’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IONS Revenue — quarterly 242.72M
IONS Net income — quarterly -109.97M
IONS EPS — quarterly -0.66

Earnings

IONS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-1.36———
Nov 9, 2026Sep 30, 2026-1.23-0.66+0.57+46.34%
Jul 29, 2026Jun 30, 2026-1.09-0.69+0.40+36.70%
Apr 29, 2026Mar 31, 2026-0.85-0.56+0.29+34.12%
Feb 25, 2026Dec 31, 2025-1.24-1.41-0.17-14.02%
Oct 29, 2025Oct 28, 2025-1.15-0.61+0.54+46.96%

Upgrades / downgrades

IONS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 18, 2026GuggenheimmainBuyBuy
Nov 10, 2026Goldman SachsmainNeutralNeutral
Nov 10, 2026Morgan StanleymainOverweightOverweight
Nov 10, 2026TD CowenmainBuyBuy
Nov 10, 2026OppenheimermainOutperformOutperform
Nov 10, 2026RBC CapitalmainOutperformOutperform

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ionis.com

News

Your note

Sign in to keep a note on IONS — it syncs with the Stock Master app.

Insider holders

IONS insider holders
InsiderRelationLatest transactionDateShares held
BAROLDI JOSEPHOfficerConversion of Exercise of derivative securityJun 25, 20260
BENNETT C FRANKOfficerSaleJul 6, 20260
BERTHELSEN SPENCER RDirectorConversion of Exercise of derivative securityJul 14, 2026161,303
BIRCHLER BRIANOfficerSaleApr 15, 202667,500
GEARY RICHARD SOfficerConversion of Exercise of derivative securityNov 5, 202559,657
HAYDEN MICHAEL REUBENDirectorPurchaseJul 30, 20260

Institution ownership

IONS institution ownership
Holder% heldSharesValueReported
FMR, LLC14.85%24,740,108673.43MSep 29, 2026
Capital World Investors13.08%21,787,273593.05MSep 29, 2026
Blackrock Inc.7.92%13,192,834359.11MSep 29, 2026
Vanguard Portfolio Management LLC4.64%7,719,464210.12MSep 29, 2026
Vanguard Capital Management LLC4.33%7,218,530196.49MSep 29, 2026
Two Sigma Investments, LP4.04%6,727,410183.12MSep 29, 2026

Fund ownership

IONS fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund5.11%8,503,655231.47MSep 29, 2026
Growth Fund of America4.60%7,668,655208.74MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.73%6,212,640169.11MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%4,989,044135.80MJun 29, 2026
New Economy Fund2.92%4,868,802132.53MSep 29, 2026
SmallCap World Fund Inc2.68%4,458,145121.35MSep 29, 2026